Ravi Salgia to Drug Resistance, Neoplasm
This is a "connection" page, showing publications Ravi Salgia has written about Drug Resistance, Neoplasm.
Connection Strength
5.659
-
Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer. Sci Adv. 2023 10 13; 9(41):eade3816.
Score: 0.723
-
Dynamic Phenotypic Switching and Group Behavior Help Non-Small Cell Lung Cancer Cells Evade Chemotherapy. Biomolecules. 2021 12 21; 12(1).
Score: 0.638
-
Group Behavior and Emergence of Cancer Drug Resistance. Trends Cancer. 2021 04; 7(4):323-334.
Score: 0.602
-
The Genetic/Non-genetic Duality of Drug 'Resistance' in Cancer. Trends Cancer. 2018 02; 4(2):110-118.
Score: 0.488
-
MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale. Mol Cancer Ther. 2017 04; 16(4):555-565.
Score: 0.460
-
Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer. Respirology. 2006 Nov; 11(6):687-92.
Score: 0.223
-
A Nexus between Genetic and Non-Genetic Mechanisms Guides KRAS Inhibitor Resistance in Lung Cancer. Biomolecules. 2023 10 28; 13(11).
Score: 0.181
-
Precision oncology provides opportunities for targeting KRAS-inhibitor resistance. Trends Cancer. 2023 01; 9(1):42-54.
Score: 0.169
-
AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer. BMC Cancer. 2022 Apr 23; 22(1):447.
Score: 0.163
-
Quantifying Cancer: More Than Just a Numbers Game. Trends Cancer. 2021 04; 7(4):267-269.
Score: 0.151
-
Activating p53 function by targeting RLIP. Biochim Biophys Acta Rev Cancer. 2021 04; 1875(2):188512.
Score: 0.150
-
RLIP: An existential requirement for breast carcinogenesis. Biochim Biophys Acta Rev Cancer. 2019 04; 1871(2):281-288.
Score: 0.131
-
Managing Patients With Relapsed Small-Cell Lung Cancer. J Oncol Pract. 2018 06; 14(6):359-366.
Score: 0.125
-
The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer. Future Oncol. 2018 Aug; 14(19):1897-1908.
Score: 0.122
-
Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL. Sci Rep. 2017 08 23; 7(1):9192.
Score: 0.118
-
Camptothecin resistance is determined by the regulation of topoisomerase I degradation mediated by ubiquitin proteasome pathway. Oncotarget. 2017 Jul 04; 8(27):43733-43751.
Score: 0.117
-
Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. Cancer Lett. 2016 10 01; 380(2):494-504.
Score: 0.110
-
Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab. Mol Cancer Ther. 2016 09; 15(9):2175-86.
Score: 0.109
-
Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy. Mol Cancer. 2014 Oct 24; 13:242.
Score: 0.097
-
Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma. J Clin Oncol. 2013 Jun 01; 31(16):e254-8.
Score: 0.087
-
MET as a possible target for non-small-cell lung cancer. J Clin Oncol. 2013 Mar 10; 31(8):1089-96.
Score: 0.086
-
Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma. Target Oncol. 2012 Sep; 7(3):199-210.
Score: 0.084
-
Personalized treatment of lung cancer. Semin Oncol. 2011 Apr; 38(2):274-83.
Score: 0.076
-
EGFR-targeted therapeutics: focus on SCCHN and NSCLC. ScientificWorldJournal. 2008 Sep 21; 8:909-19.
Score: 0.064
-
Regression of ovarian cancer xenografts by depleting or inhibiting RLIP. Biochem Pharmacol. 2023 11; 217:115847.
Score: 0.045
-
2-methoxyestradiol alters cell motility, migration, and adhesion. Blood. 2003 Jul 01; 102(1):289-96.
Score: 0.043
-
Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer. Nat Commun. 2021 05 24; 12(1):3039.
Score: 0.038
-
AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer. Clin Cancer Res. 2020 08 15; 26(16):4349-4359.
Score: 0.036
-
SOX9: The master regulator of cell fate in breast cancer. Biochem Pharmacol. 2020 04; 174:113789.
Score: 0.035
-
USP22 Interacts with PALB2 and Promotes Chemotherapy Resistance via Homologous Recombination of DNA Double-Strand Breaks. Mol Cancer Res. 2020 03; 18(3):424-435.
Score: 0.034
-
RETRACTED: The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor. Sci Signal. 2017 01 03; 10(460).
Score: 0.028
-
Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov. 2015 Aug; 5(8):850-9.
Score: 0.025
-
AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Jun 01; 21(11):2601-12.
Score: 0.025
-
AXL mediates resistance to cetuximab therapy. Cancer Res. 2014 Sep 15; 74(18):5152-64.
Score: 0.024
-
Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer. Mol Cancer Ther. 2014 May; 13(5):1356-68.
Score: 0.023
-
Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemother Pharmacol. 2008 Apr; 61(4):549-58.
Score: 0.015
-
Expression of Siva-1 protein or its putative amphipathic helical region enhances cisplatin-induced apoptosis in breast cancer cells: effect of elevated levels of BCL-2. Cancer Res. 2005 Jun 15; 65(12):5301-9.
Score: 0.013